Financial Statements Consolidated Statement of Comprehensive Income for the year ended 31 December 2014 2013 2012 Notes $m $m $m Revenue 1 26,095 25,711 27,973 Cost of sales 5,842 5,261 5,393 Gross profit 20,253 20,450 22,580 Distribution costs 324 306 320 Research and development expense 2 5,579 4,821 5,243 Selling, general and administrative costs 2 13,000 12,206 9,839 Other operating income and expense 2 787 595 970 Operating profit 2 2,137 3,712 8,148 Finance income 3 78 50 42 Finance expense 3 963 495 544 Share of after tax losses in joint ventures 10 6 Profit before tax 1,246 3,267 7,646 Taxation 4 11 696 1,376 Profit for the period 1,235 2,571 6,270 Other comprehensive income: Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit pension liability 20 766 8 13 Tax on items that will not be reclassified to profit or loss 4 216 82 65 550 74 78 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 21 823 166 106 Foreign exchange arising on designating borrowings in net investment hedges 21 529 58 46 Fair value movements on derivatives designated in net investment hedges 21 100 111 76 Amortisation of loss on cash flow hedge 1 1 1 Net available for sale gains taken to equity 245 69 72 Tax on items that may be reclassified subsequently to profit or loss 4 50 4 4 956 39 213 Other comprehensive income for the period, net of tax 1,506 113 135 Total comprehensive income for the period 271 2,458 6,405 Profit attributable to: Owners of the Parent 1,233 2,556 6,240 Non-controlling interests 2 15 30 Total comprehensive income attributable to: Owners of the Parent 266 2,470 6,395 Non-controlling interests 5 12 10 Basic earnings per $0.25 Ordinary Share 5 $0.98 $2.04 $4.95 Diluted earnings per $0.25 Ordinary Share 5 $0.98 $2.04 $4.94 Weighted average number of Ordinary Shares in issue millions 5 1,262 1,252 1,261 Diluted weighted average number of Ordinary Shares in issue millions 5 1,264 1,254 1,264 Dividends declared and paid in the period 23 3,532 3,499 3,619 All activities were in respect of continuing operations.
$m means millions of US dollars.
134 AstraZeneca Annual Report and Form 20-F Information 2014 Financial Statements Consolidated Statement of Financial Position at 31 December 2014 2013 2012 Notes $m $m $m Assets Non-current assets Property, plant and equipment 7 6,010 5,818 6,089 Goodwill 8 11,550 9,981 9,898 Intangible assets 9 20,981 16,047 16,448 Investments in joint ventures 10 59 Other investments 11 502 281 199 Derivative financial instruments 12 465 365 389 Other receivables 13 1,112 1,867 352 Deferred tax assets 4 1,219 1,205 1,111 41,898 35,564 34,486 Current assets Inventories 14 1,960 1,909 2,061 Trade and other receivables 15 7,232 7,879 7,629 Other investments 11 795 796 823 Derivative financial instruments 12 21 40 31 Income tax receivable 329 494 803 Cash and cash equivalents 16 6,360 9,217 7,701 16,697 20,335 19,048 Total assets 58,595 55,899 53,534 Liabilities Current liabilities Interest-bearing loans and borrowings 17 2,446 1,788 901 Trade and other payables 18 11,886 10,362 9,221 Derivative financial instruments 12 21 2 3 Provisions 19 623 823 916 Income tax payable 2,354 3,076 2,862 17,330 16,051 13,903 Non-current liabilities Interest-bearing loans and borrowings 17 8,397 8,588 9,409 Derivative financial instruments 12 1 Deferred tax liabilities 4 1,796 2,827 2,576 Retirement benefit obligations 20 2,951 2,261 2,271 Provisions 19 484 566 428 Other payables 18 7,991 2,352 1,001 21,619 16,595 15,685 Total liabilities 38,949 32,646 29,588 Net assets 19,646 23,253 23,946 Equity Capital and reserves attributable to equity holders of the Company Share capital 22 316 315 312 Share premium account 4,261 3,983 3,504 Capital redemption reserve 153 153 153 Merger reserve 448 433 433 Other reserves 21 1,420 1,380 1,374 Retained earnings 21 13,029 16,960 17,955 19,627 23,224 23,731 Non-controlling interests 19 29 215 Total equity 19,646 23,253 23,946 The Financial Statements from page 134 to 189 were approved by the Board on 5 February 2015 and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director AstraZeneca Annual Report and Form 20-F Information 2014 135 Financial Statements Consolidated Statement of Changes in Equity for the year ended 31 December Share Capital Total NonShare premium redemption Merger Other Retained attributable controlling Total capital account reserve reserve reserves earnings to owners interests equity $m $m $m $m $m $m $m $m $m At 1 January 2012 323 3,078 139 433 1,379 17,888 23,240 226 23,466 Profit for the period 6,240 6,240 30 6,270 Other comprehensive income 155 155 20 135 1 Transfer to other reserves 5 5 Transactions with owners Dividends 3,619 3,619 3,619 Issue of Ordinary Shares 3 426 429 429 Repurchase of Ordinary Shares 14 14 2,635 2,635 2,635 Share-based payments 79 79 79 Transfer from non-controlling interests to payables 10 10 Dividend paid by subsidiary to non-controlling interests 11 11 Net movement 11 426 14 5 67 491 11 480 At 31 December 2012 312 3,504 153 433 1,374 17,955 23,731 215 23,946 Profit for the period 2,556 2,556 15 2,571 Other comprehensive income 86 86 27 113 1 Transfer to other reserves 6 6 Transactions with owners Dividends 3,499 3,499 3,499 Issue of Ordinary Shares 3 479 482 482 Share-based payments 57 57 57 Transfer from non-controlling interests to payables 6 6 Dividend paid by subsidiary to non-controlling interests 3 3 2 Net acquisition of non-controlling interests 97 97 165 68 Net movement 3 479 6 995 507 186 693 At 31 December 2013 315 3,983 153 433 1,380 16,960 23,224 29 23,253 Profit for the period 1,233 1,233 2 1,235 Other comprehensive income 1,499 1,499 7 1,506 1 Transfer to other reserves 40 40 Transactions with owners Dividends 3,532 3,532 3,532 Issue of Ordinary Shares 1 278 279 279 Share-based payments 93 93 93 Transfer from non-controlling interests to payables 5 5 True-up to Astra AB non-controlling interest buy out 15 15 15 Net movement 1 278 15 40 3,931 3,597 10 3,607 At 31 December 2014 316 4,261 153 448 1,420 13,029 19,627 19 19,646 1 Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill.
2 Net acquisition of non-controlling interests in 2013 includes acquisitions with cash payments of $110m due in 2014 and disposals with cash of $42m received in 2013.
136 AstraZeneca Annual Report and Form 20-F Information 2014 Financial Statements Consolidated Statement of Cash Flows for the year ended 31 December 2014 2013 2012 Notes $m $m $m Cash flows from operating activities Profit before tax 1,246 3,267 7,646 Finance income and expense 3 885 445 502 Share of after tax losses of joint ventures 10 6 Depreciation, amortisation and impairment 3,282 4,583 2,518 Decrease increase in trade and other receivables 311 383 755 Decrease increase in inventories 108 135 150 Increase decrease in trade and other payables and provisions 2,089 414 1,311 Non-cash and other movements 865 258 424 Cash generated from operations 8,792 8,719 9,536 Interest paid 533 475 545 Tax paid 1,201 844 2,043 Net cash inflow from operating activities 7,058 7,400 6,948 Cash flows from investing activities Upfront payments on business acquisitions 3,804 1,158 1,187 Payment of contingent consideration on business acquisitions 18 657 Purchase of property, plant and equipment 1,012 742 672 Disposal of property, plant and equipment 158 69 199 Purchase of intangible assets 1,740 1,316 3,947 Disposal of intangible assets 35 Purchase of non-current asset investments 130 91 46 Disposal of non-current asset investments 59 38 43 Movement in short-term investments and fixed deposits 34 130 3,619 Payments to joint ventures 10 70 Dividends received 7 Interest received 140 114 145 Payments made by subsidiaries to non-controlling interests 10 10 20 Payments received by subsidiaries from non-controlling interests 42 Net cash outflow from investing activities 7,032 2,889 1,859 Net cash inflow before financing activities 26 4,511 5,089 Cash flows from financing activities Proceeds from issue of share capital 279 482 429 Repurchase of shares 2,635 Repayment of obligations under finance leases 36 27 17 Issue of loans 919 1,980 Repayment of loans 750 1,750 Dividends paid 3,521 3,461 3,665 Hedge contracts relating to dividend payments 14 36 48 Payments to acquire non-controlling interest 102 Movement in short-term borrowings 520 5 687 Net cash outflow from financing activities 2,705 3,047 4,923 Net decrease increase in cash and cash equivalents in the period 2,679 1,464 166 Cash and cash equivalents at the beginning of the period 8,995 7,596 7,434 Exchange rate effects 152 65 4 Cash and cash equivalents at the end of the period 16 6,164 8,995 7,596 AstraZeneca Annual Report and Form 20-F Information 2014 137
